

Advent Pharma Ltd.


First Quarter (Q-1) Financial Statement


(Un-audited)

For the Period Ended September 30, 2023

Advent Pharma Ltd.
Statement of Financial Position(Un-audited)
As at Sept. 30, 2023

Particulars	Notes	Amount in Tk.	
		30-Sep-2023	30-Jun-2023
ASSETS			
NON-CURRENT ASSETS		1,575,186,766	1,550,277,376
Property, Plant and Equipment	4.00	1,553,684,991	1,534,422,096
Capital Work in Progress (Building Construction)	5.00	21,501,775	15,855,280
Right of use Assets		874,249	1,019,957
CURRENT ASSETS		253,728,973	237,200,269
Inventories	6.00	81,872,172	79,748,325
Trade and Other Receivable		135,274,916	126,493,693
Advances, Deposits and Pre-payments		30,773,299	29,884,128
Cash and Cash Equivalents	7.00	5,808,586	1,074,123
Total Assets		1,829,789,988	1,788,497,602
SHAREHOLDERS' EQUITY AND LIABILITIES			
SHAREHOLDERS' EQUITY		1,431,319,091	1,399,054,064
Share Capital	8.00	931,327,320	931,327,320
Retained Earnings	9.00	499,991,771	467,726,744
NON-CURRENT LIABILITIES		187,857,016	183,123,296
Long Term Borrowings -(Net of Current Portion)		7,431,241	7,431,241
Deferred Tax Liabilities	10.00	180,092,535	175,199,510
Lease Liability (Net of Current Portion)	12.00	333,240	492,545
CURRENT LIABILITIES		210,613,881	206,320,242
Current Portion of Long Term Borrowings		7,912,963	7,912,963
Short Term Borrowings		60,901,427	54,991,768
Payable to IPO Applicants		104,355	104,355
Trade and other payables		12,409,278	20,601,042
Dividend Payable	11.00	5,093,309	6,811,912
Lease Liability (Current Portion)	12.00	782,159	764,230
Liabilities for expenses		10,446,300	10,209,945
Liability for contribution to WPPF		55,190,372	51,624,551
Provision for Current Tax	13.00	57,773,718	53,299,476
Total Liabilities		398,470,897	389,443,538
Total Shareholders' Equity and Liabilities		1,829,789,988	1,788,497,602
Net Asset Value (NAV) per Share	22.00	15.37	15.02


Company Secretary


Chief Financial Officer


Director


Managing Director


Chairman

Dated: November 14, 2023
Place: Dhaka

Advent Pharma Ltd.

Statement of Profit or Loss and Other Comprehensive Income(Un-audited) For the Period from July 01, 2023 to Sept. 30, 2023

Particulars	Notes	Amount in Taka	
		July 01, 2023 to Sept. 30, 2023	July 01, 2022 to Sept. 30, 2022
A Revenues		151,662,590	151,308,665
B Cost of Sales	14.00	(88,874,408)	(84,598,077)
C Gross Profit		62,788,182	66,710,588
Operating Expenses		(15,881,479)	(13,165,410)
D Administrative expenses	16.00	(4,423,981)	(4,159,816)
Selling & Marketing Expenses	17.00	(11,457,498)	(9,005,594)
E Operating Profit		46,906,703	53,545,178
Non Operating Expenses		(3,211,074)	(2,692,893)
F Financial Expenses	18.00	(3,211,074)	(2,692,893)
G Other Income	19.00	18,280	61,242
H Loss on Sale of Fixed Assets	20.00	-	(15,035)
I Profit Before W.P.P.F		43,713,909	50,898,492
J Expenses for W.P.P.F		(2,081,615)	(2,423,738)
K Profit Before Tax		41,632,294	48,474,754
L Income Tax Expenses		(9,367,267)	(10,751,562)
Current Tax	13.00	(4,474,242)	(5,368,837)
Deferred Tax	10.00	(4,893,025)	(5,382,725)
M Net Profit After Tax		32,265,027	37,723,192
N Other Comprehensive Income		-	-
O Total Comprehensive Income		32,265,027	37,723,192
P Earnings per Share (EPS)	21.00	0.35	0.41







Company Secretary Chief Financial Officer Director Managing Director Chairman

Dated: November 14, 2023

Place: Dhaka

Advent Pharma Ltd.
Statement of Changes in Equity(Un-audited)
For the Period from July 01, 2023 to Sept. 30, 2023

Particulars	Ordinary Share Capital	Retained Earnings	Total
Balance as on July 01, 2023	931,327,320	467,726,744	1,399,054,064
Total Comprehensive Income	-	32,265,027	32,265,027
Balance as on Sept. 30, 2023	931,327,320	499,991,771	1,431,319,091

Statement of Changes in Equity(Un-audited)
For the Period from July 01, 2022 to Sept. 30, 2022

Particulars	Ordinary Share Capital	Retained Earnings	Total
Balance as on July 01, 2022	931,327,320	382,122,337	1,313,449,657
Total Comprehensive Income	-	37,723,192	37,723,192
Balance as on Sept. 30, 2022	931,327,320	419,845,529	1,351,172,849







Company Secretary Chief Financial Officer Director Managing Director Chairman

Dated: November 14, 2023

Place: Dhaka

Advent Pharma Ltd.
Statement of Cash Flows(Un-audited)
For the Period from July 01, 2023 to Sept. 30, 2023

Particulars	Notes	Amount in Taka	
		July 01, 2023 to Sept. 30, 2023	July 01, 2022 to Sept. 30, 2022

A. CASH FLOWS FROM OPERATING ACTIVITIES:

Cash Receipts from Customers & Others	142,899,647	135,869,907
Cash Paid to Suppliers	(79,752,906)	(73,484,717)
Cash Paid to Employees	(10,403,759)	(10,204,513)
Cash Paid to Others	(9,676,628)	(7,702,175)
Tax Paid During This Period	(1,051,694)	(782,845)
Net cash generated from operating activities	42,014,660	43,695,657

B. CASH FLOWS FROM INVESTING ACTIVITIES:

Paid for Acquisition of Property, Plant & Equipment	(35,109,500)	(22,057,725)
Paid for Capital Work -in- Progress (construction)	(5,646,495)	(25,882,879)
Proceeds from Sale of Fixed Assets	-	675,000
Net cash used for investing activities	(40,755,995)	(47,265,604)

C. CASH FLOWS FROM FINANCING ACTIVITIES:


Net Received/Payment of Short Term Borrowings	5,909,659	4,069,614
Net Received/Payment of Long Term Borrowings	-	(1,132,485)
Cash Dividend Paid	(1,718,603)	(142,282)
Financial Expenses Paid	(542,758)	(942,976)
Principal portion payment of Lease Payment	(138,590)	(122,992)
Interest payment on Lease Liability	(33,910)	(49,508)
Net cash provided by financing activities	3,475,798	1,679,371

D. Net Increase/(Decrease) in cash & cash equivalents (A+B+C) **4,734,463** **(1,890,575)**

E. Cash & Cash equivalents at the beginning of the Period **1,074,123** **4,314,810**

F. Cash & Cash equivalents at the end of the Period (D+E) **5,808,586** **2,424,235**

G. Net Operating Cash Flows Per Share **0.45** **0.47**


Company Secretary




Director


Managing Director


Chairman

Dated: November 14, 2023

Place: Dhaka

Advent Pharma Ltd.

Notes, comprising a summary of significant accounting policies and other explanatory information
As at and for the Period ended 30 September, 2023

1.00 Corporate History of the Reporting Entity

Advent Pharma Limited (The Company) was incorporated in Bangladesh as a Private Limited Company under the Companies Act, 1994 vide Registration No. C-65459(2951)/2007 dated 25th January, 2007. Subsequently the company was converted into Public Company Limited by share 07 May 2016.

The registered office of the company and the factory is located at Plot # B50-54, BSCIC Industrial Estate, Dhamrai, Dhaka, Bangladesh.

2.00 Corporate Business

The Company is a Pharmaceutical company which is engaged in manufacturing, importing and marketing of animal health care drugs, nutritional supplements and feed additives for livestock like powder, bolus and liquid dosage forms. All products have duly been approved by Drug Administration Authority and Department of Live Stock respectively.

3.00 Basis of preparation and significant accounting policies

The financial statements of the company have been prepared on going concern assumption under historical cost convention, on accrual basis and in accordance with the International Accounting Standards (IASs), International Financial Reporting Standards (IFRSs), the Companies Act 1994, the Securities and Exchange Rules 2020, the requirements of Financial Reporting Act 2015, Value Added Tax and Supplementary Duty Act 2012, Income Tax Ordinance 1984, Income Tax Act 2023 and other laws and regulations applicable for the company.

The following International Accounting Standards were applied for the preparation of the financial statements for the period.

IAS 1	Presentation of Financial Statements
IAS 2	Inventories
IAS 7	Statement of Cash Flows
IAS 8	Accounting Policies, Changes in Accounting Estimates and Errors
IAS 10	Events after the Reporting Period
IAS 12	Income Taxes
IAS 16	Property, Plant and Equipment
IAS 19	Employee Benefits
IAS 23	Borrowing Costs
IAS 24	Related Party Disclosures
IAS 32	Financial Instruments: Presentation
IAS 33	Earnings per Share
IAS 34	Interim Financial Reporting
IAS 36	Impairment of Assets
IAS 37	Provisions, Contingent Liabilities and Contingent Assets
IFRS 7	Financial Instruments: Disclosures
IFRS 8	Operating Segments
IFRS 9	Financial Instruments
IFRS 13	Fair Value Measurement
IFRS 15	Revenue from Contracts with Customers
IFRS 16	Leases



4.00 Property, Plant and Equipment**A. Cost**

Opening Balance

Add: Addition during the period

Less: Disposal during the period

B. Accumulated Depreciation

Opening Balance

Add: Depreciation charged during the period

Less: Adjustment during the period

Written down Value (A-B)*Details are shown in Annexure-A.***5.00 Capital Work In Progress (Building Construction)**

Opening Balance

Addition during the period

Transfer to Factory Building

Closing Balance**6.00 Inventories**

Finished Goods (Note-14.00)

Raw Materials

Packing Materials

Spare Parts

Work In Process (Note-14.00)

Total**7.00 Cash & Cash Equivalents**

Cash in hand (Note-7.01)

Cash at bank (Note-7.02)

Total**7.01 Cash in Hand**

Head Office

Depots

Total

Cash in hand has been certified by the management of the company.

7.02 Cash at Bank**7.02.01 Cash at Bank****Bank Name**

Islami Bank Bangladesh Ltd.

Islami Bank Bangladesh Ltd.

Dutch Bangla Bank Ltd.

Janata Bank Ltd.

IFIC Bank Ltd.

IFIC Bank Ltd.

IFIC Bank Ltd.

Shahjalal Islami Bank Ltd.

Midland Bank Ltd.

BRAC Bank Ltd.

BRAC Bank Ltd.

Standard Bank Ltd.

Total

A/C No. # 283517
A/C No. # 453011
A/C No. # 129775
A/C No. # 10035785
A/C No. # 327-041
A/C No. # 327-001
A/C No. # 327-003
A/C No. # 000-7339
A/C No. # 000-6230
A/C No. # 150001
A/C No. # 150002
A/C No. # 012548

Amount in Taka	
30-Sep-2023	30-Jun-2023

1,786,432,275	1,594,898,865
35,109,500	193,614,435
-	(2,081,025)
1,821,541,775	1,786,432,275
252,010,179	194,800,650
15,846,605	58,600,519
-	(1,390,990)
267,856,784	252,010,179
1,553,684,991	1,534,422,096

15,855,280	7,386,999
5,646,495	130,503,926
-	(122,035,645)
21,501,775	15,855,280

38,686,263	34,109,497
25,036,282	23,670,264
5,961,260	7,366,928
42,585	78,512
12,145,782	14,523,124
81,872,172	79,748,325

205,994	122,593
5,602,592	951,530
5,808,586	1,074,123

205,801	110,839
193	11,754
205,994	122,593

5,602,592	951,530
-----------	---------

166,124	267,195
9,569	9,569
188,750	272,644
120,173	7,452
752,535	14,793
115,116	10,847
100,125	168,728
110,822	11,582
162,064	16,264
93,289	93,634
78,822	78,822
3,705,203	-
5,602,592	951,530



8.00 Share Capital

Authorized Capital:

100,000,000 ordinary shares of Tk. 10.00 each

Issued, Subscribed & Paid-up Capital:

931,32,732 ordinary shares of Tk. 10.00 each

Amount in Taka	
30-Sep-2023	30-Jun-2023

1,000,000,000 1,000,000,000

931,327,320 931,327,320

Share holding position of Shareholders:

Category of Shareholders	No. of Share Holding		Percentage of Shareholding		Amount in Taka	
	30-Sep-23	30-Jun-23	30-Sep-23	30-Jun-23	30-Sep-2023	30-Jun-2023
Director & Sponsor	27,957,751	27,957,751	30.02%	30.02%	279,577,510	279,577,510
Institutional	13,552,857	21,294,226	14.55%	22.86%	135,528,570	212,942,260
Public	51,622,124	43,880,755	55.43%	47.12%	516,221,240	438,807,550
Total	93,132,732	93,132,732	100.00%	100.00%	931,327,320	931,327,320

9.00 Retained Earnings

Opening balance	467,726,744	382,122,337
Add: Profit for the period	32,265,027	98,639,403
Cash Dividend	-	(13,034,996)
Closing balance	499,991,771	467,726,744

10.00 Deferred Tax Liabilities

Opening Balance	175,199,510	148,562,219
Add: Provision made during the period (Note-10.01)	4,893,025	26,637,291
Closing Balance	180,092,535	175,199,510

10.01 Deferred tax liabilities as at Sept. 30, 2023 is arrived as follows :

Written Down Value of PPE as per Accounting Base	1,553,684,991	1,534,422,096
Written Down Value as per Third Schedule	(753,273,726)	(755,757,607)
Net Temporary Difference	800,411,265	778,664,489
Income Tax Rate	22.50%	22.50%
Deferred Tax Liability	180,092,535	175,199,510
Opening Deferred Tax Liability	(175,199,510)	(148,562,219)
Deferred Tax Expenses	4,893,025	26,637,291

11.00 Dividend Payable:

Dividend payable (2021-2022)	4,050,798	5,769,401
Dividend payable (2020-2021)	287,163	287,163
Dividend payable (2020-2021)-Fraction	3,837	3,837
Dividend payable (2019-2020)-Fraction	2,084	2,084
Dividend payable (2018-2019)	749,427	749,427
Total	5,093,309	6,811,912

12.00 Liability for Leases net of current Maturity:

Opening Balance	1,256,775	1,724,406
Add: Interest Expenses	31,124	164,869
Less: Payment	(172,500)	(632,500)
Closing Balance	1,115,399	1,256,775
Less: Lease Liability (Current Portion)	(782,159)	(764,230)
Total	333,240	492,545



13.00 Provision for Current Tax

Opening Balance
Add: Provision for tax during the period (Note-13.01)
Less: Paid during the period/Adjustment
Closing Balance

Amount in Taka	
30-Sep-2023	30-Jun-2023
53,299,476	55,601,998
4,474,242	3,349,382
-	(5,651,904)
57,773,718	53,299,476

13.01 Provision for Tax during the period

(A) Regular

Accounting Profit before Tax
Add: Other Inadmissible Allowances
Accounting Depreciation
Other Income
Less: Items for Separate Consideration
Depreciation as per 3rd Schedule
Total Taxable Income
Rate
Total Tax Expenses/Current Tax
Tax on other income
Adjustment for previous period:
For the Income year 2017-2018
Total Tax Payable

41,632,294	128,626,076
15,846,605	58,600,519
3,476,223	(8,936,561)
(37,593,381)	(177,678,513)
23,361,741	611,521
22.50%	22.50%
5,256,392	137,592
(782,150)	2,010,726
-	(1,656,554)
4,474,242	491,764

(B) Minimum Tax

Revenue from Sales
Other Income
Total Revenue
Rate of Tax
Minimum Tax

148,204,647	549,293,830
3,476,223	8,936,561
151,680,870	558,230,391
0.60%	0.60%
910,085	3,349,382

(C) Advance Tax

219,564	2,437,576
----------------	------------------

Provision for the period (whichever is Higher)

4,474,242	3,349,382
------------------	------------------



Amount in Taka	
July 01, 2023 to Sept. 30, 2023	July 01, 2022 to Sept. 30, 2022

14.00 Cost of Sales

Raw Materials Consumed	67,544,500	67,349,077
Manufacturing Overhead (Note-15.00)	24,024,302	18,802,031
	91,568,802	86,151,108
Add: Opening Work in process	14,523,124	12,396,345
Less: Closing Work in process	(12,145,782)	(14,513,545)
Cost of Goods manufactured	93,946,144	84,033,908
Add: Opening stock of finished Goods	34,109,497	33,685,358
Cost of Goods Available for Sale	128,055,641	117,719,266
Less: Closing stock of finished Goods	(38,686,263)	(32,708,629)
Less: Sample Distribution	(494,970)	(412,560)
Cost of Sales	88,874,408	84,598,077

15.00 Manufacturing Overhead

Wages and Salary	3,016,600	2,709,845
Overtime	53,505	280,707
Packaging Materials Consumed	3,628,759	2,834,227
Spare Parts Consumed	155,522	156,898
Repair & Maintenance	207,120	295,537
Electricity Bill	417,508	417,239
Disel & Fuel	37,060	137,260
Electric & Sanitary Goods	9,100	34,108
Fire Insurance Premium	22,032	53,206
Canteen Expenses	473,800	501,073
Conveyance	12,640	15,860
Miscellaneous Expenses	7,750	3,844
Newspaper & Magazine	1,090	1,110
Laboratory Expenses	31,600	-
Photocopy, Printing & Stationery	40,530	92,195
Cleaning & Washing	19,720	21,570
Internet bill	7,500	7,500
Mobile & Telephone bill	11,550	8,780
Uniform	19,780	31,350
Toll Charges	380,426	373,572
Depreciation (Annexure-A)	15,470,710	10,826,150
Total	24,024,302	18,802,031

16.00 Administrative Expenses

Salary & Allowance	2,288,567	2,055,000
Director Salary (Note # 44.01)	300,000	300,000
Conveyance	13,250	25,758
Subscription, Gift & Donation	3,750	23,887
Board meeting attendance fees (Note # 44.01)	45,000	45,000
Cleaning & Sanitation	5,925	20,854
Electricity Bill	75,537	60,863
Entertainment	61,523	68,807
Garage Rent	6,000	5,400



Legal, License & Renewal & Professional fee
Miscellaneous Expense
Newspaper & Magazine
Postage, Stamps & Courier
Printing & Stationery
Office Maintenance
Repair & Maintenance
Fuel & Gas
Telephone & Mobile
Internet bill
Audit Fees Including VAT
Depreciation Charge for the Right-of-Use Asset
Depreciation (Annexure-A)

Total

Amount in Taka	
July 01, 2023 to Sept. 30, 2023	July 01, 2022 to Sept. 30, 2022
98,193	185,971
502,017	316,960
876	784
2,200	2,990
65,233	47,961
51,860	52,080
100,380	71,890
167,577	240,531
29,990	31,674
27,000	27,000
57,500	57,500
145,708	145,708
375,895	373,198
4,423,981	4,159,816

Note: Interest expenses on the leased liability transferred to the Financial Expenses.

17.00 Selling & Marketing Expenses

Salary & Allowance
Travelling & Conveyance
Festival Bonus
Advertisement
Marketing Promotion
Distribution Cost
Bad Debts Expenses
Sample Distribution

Total

5,038,033	4,098,600
1,914,160	1,347,230
-	410,364
20,830	8,103
1,658,500	507,295
2,325,596	2,221,442
5,409	-
494,970	412,560
11,457,498	9,005,594

18.00 Financial Expenses

Bank Charges
Interest on Loan
Interest on W.P.P.F used
Interest expenses on lease liability

Total

68,661	63,526
1,627,083	1,417,034
1,484,206	1,165,297
31,124	47,036
3,211,074	2,692,893

19.00 Other Income

Bank Interest
Sales of Wastage

Total

-	-
18,280	61,242
18,280	61,242

20.00 Other Loss

Loss on disposal of Fixed Assets

Total

-	15,035
-	15,035



21.00 Earnings Per Share

Basic Earnings per Share

Profit after tax

Weighted average number of ordinary shares outstanding(Note-21.01)

Basic Earnings per Share

As there is no shares under Option, Basic & Diluted earnings per share are same for the year. This has been calculated in compliance with the requirement of IAS 33 Earnings per share. EPS is the basic earnings dividing by the weighted average number of ordinary shares outstanding at the end of the period.

Quarterly Product	
30-Sep-2023	30-Sep-2022
32,265,027	37,723,192
93,132,732	93,132,732
0.35	0.41

21.01 Calculation of Weighted Average Number of Shares

Particulars	Share Numbers	Outstanding Period	Length in Days	Daily Product	Quarterly Product (Weighted Average)	
					30-Sep-2023	30-Sep-2022
Shares at beginning	93,132,732	July-23 to Sept.-23	92	8,568,211,344	93,132,732	93,132,732
Total	93,132,732			8,568,211,344	93,132,732	93,132,732

22.00 Net Asset Value (NAV) per Share

Total Asset

Less: Total Outside Liability

Net Asset

Number of ordinary shares outstanding

Net Assets Value (NAV) per Share

Amount in Taka	
30-Sep-2023	30-Jun-2023
1,829,789,988	1,788,497,602
398,470,897	389,443,538
1,431,319,091	1,399,054,064
93,132,732	93,132,732
15.37	15.02

23.00 Net Operating Cash Flows per Share(NOCFPS)

Net Cash Generated From Operating Activities

Weighted Average Number of Shares Outstanding

Net Operating Cash Flows per Share(NOCFPS)

Amount in Taka	
30-Sep-2023	30-Sep-2022
42,014,660	43,695,657
93,132,732	93,132,732
0.45	0.47

24.00 Reconciliation of Net Profit with Cash flows from Operating Activities:

Profit before Tax

Adjustment for:

Depreciation on property, plant and equipment

Adjustment for depreciation of the Right Use of Assets

Interest expenses on Lease

Financial Expenses

Loss on disposal of Fixed Assets

(Increase)/Decrease in Accounts Receivable

(Increase)/Decrease in Inventory

Increase/(Decrease) in Trade and Other Payables

Decrease/(Increase) in Advance, Deposit & Prepayments

Increase/(Decrease) in Liabilities for Expenses

Increase/(Decrease) in Liability for contribution to W.P.P.F

Less: Income Tax Paid

Net Cash Generated from Operating Activities

41,632,294	48,474,754
15,846,605	11,199,348
145,708	145,708
31,124	47,036
3,179,950	2,645,857
-	15,035
60,835,681	62,527,738
(8,781,223)	(15,500,000)
(2,123,847)	(2,315,326)
(8,191,764)	(2,811,919)
162,523	1,519,134
(916,631)	(1,317,827)
2,081,615	2,423,738
43,066,354	44,525,537
(1,051,694)	(782,845)
42,014,660	43,742,693



25.00 Related parties Transaction:

As per International Accounting standards IAS 24 Related Party Disclosures, Parties are considered to be related if one of the party has the ability to control the other party or exercise significant influence over the other party in making financial and operating decision.

25.01 As per paragraph 17 of IAS 24: Disclosure of key management personnel compensation.**a) Short-term employee benefits :**

The amount of transaction for remuneration and board meeting fee during the period from 1st July 2023 to 30 th September 2023 are as follows:

Name	Designation	Remuneration	Board Meeting fee
Asif Iqbal Chowdhury	Chairman	-	5,000
Faria Binta Alam	Managing Director	300,000	5,000
Wajhi Ahmed	Director	-	5,000
Kazi Rina Alam	Director	-	5,000
Md. Tazul Islam	Director	-	5,000
Mohammad Towhidul Islam	Nominee Director	-	5,000
Dr. Khandaker Sagir Ahmed	Nominee Director	-	5,000
Mohammed Salim	Independent Director	-	5,000
Sheikh Karimuzzaman	Independent Director	-	5,000
Total		300,000	45,000

b) Post employment benefits: Nil

c) Other long term benefits: Nil

d) Termination benefits: Nil

e) Share-based payment: Nil

26.00 Significant Deviation

Advent Pharma Ltd. is veterinary medicine manufacturer. During the period our sales has increased and materials & other costs has also increased. As a result net profit after tax and earnings per share has decreased. Net operating cash flow per also decreased due to increase of payment to suppliers, employees from previous period.



Advent Pharma Ltd.
Schedule of Property, Plant and Equipment
As at Sept. 30, 2023

Annexure-A
(Amount in Taka)

Particulars	Cost			Rate of Dep.	Depreciation				Written down value as on 30-Sept.-2023
	Balance as on 01-July-2023	Addition during the Period	Disposal during the Period		Balance as on 01-July-2023	Charged during the Period	Adjustment during the Period	Balance as on 30-Sept.-2023	
Land	3,783,816	-	-	0%	-	-	-	-	3,783,816
Land Development	9,454,530	-	-	2.5%	1,433,969	50,129	-	1,484,098	7,970,432
Factory Building	1,245,224,262	-	-	2.5%	103,213,699	7,137,566	-	110,351,265	1,134,872,997
Plant & Machinery	358,770,184	35,109,500	-	10%	90,680,223	6,994,828	-	97,675,051	296,204,633
Sub-Station	6,694,722	-	-	10%	3,787,153	72,689	-	3,859,842	2,834,880
Motor Vehicle	5,427,957	-	-	15%	2,397,505	113,642	-	2,511,147	2,916,810
Furniture & Fixture	8,267,390	-	-	10%	3,994,563	106,821	-	4,101,384	4,166,006
Solar Panel	2,004,740	-	-	10%	1,098,120	22,666	-	1,120,786	883,954
Generator	627,520	-	-	10%	415,808	5,293	-	421,101	206,419
Air Conditioner	4,254,120	-	-	10%	1,517,389	68,418	-	1,585,807	2,668,313
Office Equipment	6,745,713	-	-	10%	3,265,171	87,014	-	3,352,185	3,393,528
HVAC System	44,536,240	-	-	5%	13,298,513	390,472	-	13,688,985	30,847,255
Laboratory Equipment	51,381,830	-	-	5%	15,274,799	451,338	-	15,726,137	35,655,693
Product Development Equipment	20,725,781	-	-	5%	6,140,363	182,318	-	6,322,681	14,403,100
ETP	18,488,470	-	-	5%	5,464,027	162,806	-	5,626,833	12,861,637
Books & Journals	45,000	-	-	15%	28,877	605	-	29,482	15,518
Total	1,786,432,275	35,109,500	-		1,821,541,775	15,846,605	-	267,856,784	1,553,684,991

Allocation of Depreciation:

Administrative cost	375,895
Factory cost	15,470,710
Total	15,846,605



Advent Pharma Ltd.
Schedule of Property, Plant and Equipment
As at Sept. 30, 2022

Annexure-A
(Amount in Taka)

Particulars	Cost				Rate of Dep.	Depreciation				Written down value as on 30-Sept.-2022
	Balance as on 01-July-2022	Addition during the Period	Disposal during the Period	Balance as on 30-Sept.-2022		Balance as on 01-July-2022	Charged during the Period	Adjustment during the Period	Balance as on 30-Sept.-2022	
Land	3,783,816	-	-	3,783,816	0%	-	-	-	3,783,816	
Land Development	9,454,530	-	-	9,454,530	2.5%	1,228,314	51,414	-	8,174,802	
Factory Building	1,123,188,617	-	-	1,123,188,617	2.5%	76,278,216	6,543,190	-	1,040,367,211	
Plant & Machinery	288,743,534	20,033,425	-	308,776,959	10%	66,344,445	2,869,601	-	239,562,913	
Sub-Station	6,694,722	-	-	6,694,722	10%	3,464,090	80,766	-	3,149,866	
Motor Vehicle	6,158,982	1,350,000	2,081,025	5,427,957	15%	3,264,831	125,030	1,390,990	3,429,086	
Furniture & Fixture	8,228,450	-	-	8,228,450	10%	3,523,580	117,622	-	4,587,248	
Solar Panel	2,004,740	-	-	2,004,740	10%	997,384	25,184	-	982,172	
Generator	627,520	-	-	627,520	10%	392,284	5,881	-	229,355	
Air Conditioner	4,254,120	40,300	-	4,294,420	10%	1,213,308	38,010	-	3,043,102	
Office Equipment	6,582,513	-	-	6,582,513	10%	2,888,076	92,536	-	3,601,901	
HVAC System	44,536,240	-	-	44,536,240	5%	11,654,422	411,023	-	32,470,795	
Laboratory Equipment	51,381,830	-	-	51,381,830	5%	13,374,429	475,093	-	37,532,308	
Product Development Equipment	20,725,781	-	-	20,725,781	5%	5,372,709	191,913	-	15,161,159	
ETP	18,488,470	-	-	18,488,470	5%	4,778,530	171,374	-	13,538,566	
Books & Journals	45,000	-	-	45,000	15%	26,032	711	-	18,257	
Total	1,594,898,865	21,423,725	2,081,025	1,614,241,565		194,800,650	11,199,348	1,390,990	1,409,632,557	

Allocation of Depreciation:

Administrative cost	373,198
Factory cost	10,826,150
Total	11,199,348



